Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.

Diabetes risk higher in postmenopausal women with breast cancer

22 Jul 2019

The risk of diabetes mellitus (DM) is higher among postmenopausal women who develop primary breast cancer, reports a new study.

Accessing the Taiwan National Health Insurance Research Database, researchers identified 4,607 postmenopausal women (mean age, 58.6±9.1 years) with primary breast cancer and 23,035 matched noncancer controls (mean age, 58.6±9.1 years). Cox proportional hazards analysis was performed to assess the relationship between breast cancer and DM risk.

The incidence rates of DM at 1, 5, 10 and 15 years after cancer diagnosis were 92.6, 49.5, 41.9 and 39.9 events per 1,000 person-years, respectively. In the same time span since the index date, the corresponding rates in controls were lower, at 53.6, 27.2, 24.5 and 24.0 events per 1,000 person-years.

Models adjusted for age, income, urbanization, comorbidities and other medical conditions further showed that the risk of DM 1 year after index date was significantly higher in those with breast cancer (adjusted hazard ratio [HR], 1.70, 95 percent CI, 1.40–2.05).

The same was true when DM risk was assessed at 5 (adjusted HR, 1.34, 1.17–1.54), 10 (adjusted HR, 1.27, 1.13–1.44) and 15 (adjusted HR, 1.24, 1.11–1.40) years.

Stratifying according to hormone therapy showed that at 1 year, women who were receiving hormone therapy were more likely to develop DM than those who were not, though significance was not achieved (adjusted HR, 1.22, 0.86–1.74). This indicated that the effect of breast cancer on DM risk was independent of hormone therapy, said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.